HUTCHMED China Ltd - Asset Resilience Ratio
HUTCHMED China Ltd (HCM) has an Asset Resilience Ratio of 70.66% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check HUTCHMED China Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how HUTCHMED China Ltd's Asset Resilience Ratio has changed over time. See HCM equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down HUTCHMED China Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HCM company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.25 Billion | 70.66% |
| Total Liquid Assets | GBX1.25 Billion | 70.66% |
Asset Resilience Insights
- Very High Liquidity: HUTCHMED China Ltd maintains exceptional liquid asset reserves at 70.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
HUTCHMED China Ltd Industry Peers by Asset Resilience Ratio
Compare HUTCHMED China Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 6.06% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 3.28% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
Annual Asset Resilience Ratio for HUTCHMED China Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for HUTCHMED China Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.54% | GBX682.15 Million ≈ $83.00K |
GBX1.27 Billion ≈ $155.03K |
+6.44pp |
| 2023-12-31 | 47.10% | GBX602.75 Million ≈ $73.34K |
GBX1.28 Billion ≈ $155.71K |
+16.23pp |
| 2022-12-31 | 30.86% | GBX317.72 Million ≈ $38.66K |
GBX1.03 Billion ≈ $125.25K |
-15.34pp |
| 2021-12-31 | 46.20% | GBX634.16 Million ≈ $77.16K |
GBX1.37 Billion ≈ $167.01K |
+18.64pp |
| 2020-12-31 | 27.56% | GBX199.55 Million ≈ $24.28K |
GBX724.12 Million ≈ $88.10K |
+6.37pp |
| 2019-12-31 | 21.19% | GBX98.54 Million ≈ $11.99K |
GBX465.12 Million ≈ $56.59K |
-19.20pp |
| 2018-12-31 | 40.39% | GBX214.91 Million ≈ $26.15K |
GBX532.12 Million ≈ $64.74K |
-5.27pp |
| 2017-12-31 | 45.66% | GBX273.03 Million ≈ $33.22K |
GBX597.93 Million ≈ $72.75K |
+38.58pp |
| 2016-12-31 | 7.09% | GBX24.27 Million ≈ $2.95K |
GBX342.44 Million ≈ $41.66K |
+6.74pp |
| 2015-12-31 | 0.35% | GBX800.00K ≈ $97.34 |
GBX229.75 Million ≈ $27.95K |
-5.37pp |
| 2014-12-31 | 5.72% | GBX12.53 Million ≈ $1.52K |
GBX218.94 Million ≈ $26.64K |
+3.09pp |
| 2010-12-31 | 2.64% | GBX4.21 Million ≈ $512.83 |
GBX159.93 Million ≈ $19.46K |
-42.87pp |
| 2006-12-31 | 45.51% | GBX60.54 Million ≈ $7.37K |
GBX133.04 Million ≈ $16.19K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more